Praetego is pioneering a groundbreaking class of drugs known as Amadorins. Our mission is to protect patients from debilitating age-related neurodegeneration, with a focus on Alzheimer’s disease. Praetego is committed to limiting Alzheimer's disease, thereby enhancing the overall aging experience. With a successful pre-IND meeting completed, our lead, PTG-630, is ready for IND-enabling, and aiming for clinic within 12 months. Our approach centers on mitigating the impact of Advanced Glycation End-products (AGEs), commonly referred to as glycotoxins, generated during the essential process of glucose metabolism. AGEs wreak havoc on the body as it ages. These compounds drive aberrant protein aggregation, chronic inflammation, oxidative stress, and, ultimately, organ damage. Praetego's Amadorins act as a powerful counterforce, inhibiting the formation of AGEs, offering an early deterrent to age-related neurodegeneration and Alzheimer’s disease.